Type 2 Diabetes Treatment Market to reach $120.1 billion by 2035

Type 2 Diabetes Treatment market was valued at $66.4 billion in 2025 and is projected to reach $120.1 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026-2035). The increasing prevalence of type 2 diabetes continues to form a strong foundation for sustained market expansion. According to the International Diabetes Federation, approximately 589 million adults were living with diabetes in 2024, representing nearly one in nine adults, with projections indicating a rise to 853 million by 2050. This consistent increase reflects long-term structural shifts such as ageing populations, urbanization, and dietary transitions. In India alone, the diabetic population reached nearly 89.8 million adults in 2024, with prevalence estimated at 10.5%, and is expected to grow significantly in the coming decades. The disease burden is further intensified by a high proportion of undiagnosed cases, with estimates suggesting that over 40% of individuals remain unaware of their condition, leading to delayed treatment initiation. Urban populations show higher prevalence levels compared to rural areas, driven by sedentary lifestyles and increased obesity rates. These factors collectively expand the addressable patient pool, thereby increasing demand for pharmacological therapies, insulin formulations, and monitoring devices. As diagnosis rates improve through screening initiatives and awareness programs, a larger share of patients enters the formal treatment pathway, directly contributing to market revenue generation.

Browse the full report description of “Type 2 Diabetes Treatment Market Size, Share & Trends Analysis Report by Drug Class (Biguanides, Sulfonylureas, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Thiazolidinediones, Alpha-glucosidase Inhibitors, Insulin, and Others), by Devices (Insulin Pumps, Insulin Pen, Blood Glucose Meters, and Others), by End User (Hospitals, Specialty Diabetes Clinics, and Homecare Settings), Forecast Period (2026–2035” at https://www.omrglobal.com/industry-reports/type-2-diabetes-market

The progression of type 2 diabetes toward younger demographics further reinforces long-term treatment demand and lifetime therapy dependence. Clinical observations indicate a rising incidence among individuals below 40 years, with prevalence levels reaching over 17% in certain younger population groups, highlighting a shift in disease onset patterns. The chronic nature of the condition requires continuous management, including medication adherence, glucose monitoring, and device utilization, resulting in recurring revenue streams for market participants. In addition, more than 80% of individuals with diabetes reside in low- and middle-income countries, where healthcare access is improving, leading to increased treatment penetration. Government-led healthcare initiatives and expanded insurance coverage are further supporting access to essential medicines and advanced therapies. The steady rise in comorbid conditions such as cardiovascular disease and obesity has also encouraged the adoption of newer drug classes with multi-benefit profiles. These structural and epidemiological factors ensure a consistent increase in treated patient volumes, supporting long-term growth of the type 2 diabetes treatment market.

Innovation Leaders Transforming the Type 2 Diabetes Treatment Market

The key players in the type 2 diabetes treatment market include Abbott Laboratories, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Medtronic Plc, among others. These companies are advancing innovation in type 2 diabetes treatment through the development of next-generation pharmacological therapies, including incretin-based drugs, improved insulin analogs, and combination treatment regimens, alongside digitally integrated delivery devices such as insulin pumps and continuous glucose monitoring systems, enabling more precise glycemic control, enhanced patient adherence, and long-term disease management while addressing the growing clinical and economic burden associated with chronic metabolic disorders.

• In January 2026, AstraZeneca announced a collaboration with CSPC Pharmaceuticals to develop next-generation peptide therapies for diabetes and obesity. The agreement includes access to AI-driven drug discovery platforms and long-acting dosing technologies, improving treatment convenience and efficacy.
• In December 2025, Biocon Limited entered into an out-licensing agreement with Ajanta Pharma to commercialize semaglutide across emerging markets. This move is expected to expand the availability of GLP-1 therapies across regions with rising diabetes prevalence.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Class
  • By Devices
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Abbott Laboratories, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Medtronic Plc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Type 2 Diabetes Treatment Market Report Segment

By Drug Class

• Biguanides
• Sulfonylureas
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors
• Thiazolidinediones
• Alpha-glucosidase Inhibitors
• Insulin
• Others

By Devices

• Insulin Pumps
• Insulin Pen
• Blood Glucose Meters
• Others

By End User

• Hospitals
• Specialty Diabetes Clinics
• Homecare Settings

Global Type 2 Diabetes Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/type-2-diabetes-market